Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABL and JAK Kinase Inhibitors With Chemotherapy and Venetoclax in Ph-like ALL
NCT07454226Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- May 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olverembatinib, jaktinib in acute lymphoblastic leukemia (ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started May 2026; status: recruiting.
02
Drugs
olverembatinibjaktinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07454226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07454226.